Sentiment Trading

Beam Therapeutics Inc. reported a larger-than-expected loss in its first-quarter 2025 financial results, but remains committed to advancing its clinical programs and achieving long-term stability.

Beam Therapeutics Inc. reported a $109.27 million loss in Q1 2025, exceeding last year’s figures and analyst expectations, but projects financial stability through 2028.